Clinical trials: Adverse Effect
Bipolar Disorder
Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression
Evaluation of the impact of the genetic variation of individual genes on the therapeutic response and side effects profile in a cohort of well-characterized patients with bipolar depression, using NEUROPHARMAGEN.
- Trial name
- NCT04923204
- Testing
- Pharmacogenomic-testing with NEUROPHARMAGEN
- Where
- Spain
- Volunteers
- 76 people
- Sponsor
- AB Biotics, SA
Fatigue, Neoplasms
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
- Trial name
- NCT00047476
- Testing
- dexmethylphenidate(d-mph)
- Where
- 21 sites in United States
- Volunteers
- 160 people
- Sponsor
- Celgene Corporation
Breast Neoplasm, Ovary Cancer
Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy
Chemotherapies often induce side effects. This study examines whether hypnosis, music therapy versus standard therapy influence these side effects.
- Trial name
- F-Chem (NCT03740984)
- Testing
- Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.
- Where
- 3 sites in Germany
- Volunteers
- 81 people
- Sponsor
- Dr. Horst Schmidt Klinik GmbH
Drug-Induced Liver Injury, Cholestatic Liver Injury
A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects
The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI)…
- Conditions
- Drug-Induced Liver Injury, Cholestatic Liver Injury, Mixed Liver Injury
- Trial name
- NCT06019936
- Testing
- MT2004 Capsule
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xi'An Aolitai Pharmaceutical Technology Co Ltd
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
- Trial name
- NCT07241390
- Testing
- Orforglipron
- Where
- 566 sites in Argentina, Australia and 36 more
- Volunteers
- 7,140 people
- Sponsor
- Eli Lilly and Company